РЕЗУЛЬТАТЫ ЛЕЧЕНИЯ МУЛЬТИРЕЗИСТЕНТНОГО ТУБЕРКУЛЕЗА С ИСПОЛЬЗОВАНИЕМ НОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ И КЛЕТОЧНЫХ ТЕХНОЛОГИЙ

Мультирезистетный туберкулез является одной из актуальных проблем здравоохранения в Республике Беларусь.

Цель исследования – оценка эффективности новых лекарственных средств и схем химиотерапии, а также клеточных технологий как метода аддитивной терапии при лечении пациентов с туберкулезом с множественной и широкой лекарственной устойчивостью возбудителя (М/ШЛУ-ТБ).

Для оценки эффективности лечения на основании когортного анализа было отобрано 416 человек, которым были назначены новые схемы химиотерапии. Мультирезистентный туберкулез у пациентов выявляли с помощью оптимизированного алгоритма микробиологической диагностики с применением молекулярно-генетических методов. Разработана методика аутологичной трансплантации мультипотентных мезенхимальных стромальных клеток, входящая в комплексную схему лечения пациентов с М/ШЛУ-ТБ.

Предварительные результаты исследования свидетельствуют о высокой эффективности новых противотуберкулезных схем, а также клеточной технологии на фоне индивидуализированной химиотерапии в лечении лекарственно-устойчивого туберкулеза. При этом установлено, что бедаквилин и деламанид эффективны в сочетании с оптимизированными фоновыми схемами лечения, состоящими в том числе из перепрофилированных противотуберкулезных лекарственных средств, и вызывают незначительное количество побочных явлений. 

1. Global tuberculosis report 2016 / World Health Organization. – Geneva : World Health Organization Publ., 2016. – 214 p.

2. Гуревич, Г. Л. Туберкулез: возбудитель, патогенез, риск заболевания, эпидемиология / Г. Л. Гуревич, О. М. Калечиц // Мир медицины. – 2012. – № 5. – С. 3–4.

3. World Health Organization, the HWO/IUATLD Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis Drug Resistance in the World: Forth Global Report. WHO/HTM/TB/2008.394. – Geneva : World Health Organization Publ., 2008. – 64 p.

4. Влияние множественной лекарственной устойчивости на эффективность лечения больных туберкулезом / Е. М. Скрягина [и др.] // Рецепт. – 2010. – № 1. – С. 61–66.

5. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors / A. Skrahina [et al.] // Bull. of the World Health Organization. – 2013. – Vol. 91, N 1. – P. 36–45.

6. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes / D. Falzon [et al.] // Europ. Respiratory J. – 2013. – Vol. 42, N 1. – P. 156–168.

7. Drug resistance beyond extensively drug resistant tuberculosis: individual patient data meta-analysis / G. B. Migliori [et al.] // Europ. Respiratory J. – 2013. – Vol. 42, N 1. – P. 169–179.

8. Frequency of recurrence among MDR-TB cases «successfully» treated with standardised short-course chemotherapy / G. B. Migliori [et al.] // Intern. J. of Tuberculosis and Lung Disease. – 2002. – Vol. 6, N 10. – P. 858–864.

9. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation / R. Diel [et al.] // Europ. Respiratory J. – 2014. – Vol. 43, N 2. – P. 554–565.

10. Caminero, J. A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence / J. A. Caminero, A. Scardigli // European Respiratory J. – 2014. – Vol. 46, N 4. – P. 887–893.

11. Sotgiu, G. Linezolid to treat MDR-/XDR-Tuberculosis: available evidence and future scenarios / G. Sotgiu, E. Pontali, G. B. Migliori // Europ. Respiratory J. – 2015. – Vol. 45, N 1. – P. 25–29.

12. Tuberculosis: cost of illness in Germany / R. Diel [et al.] // Europ. Respiratory J. – 2012. – Vol. 40, N 1. – P. 143–151.

13. First tuberculosis cases in Italy resistant to all tested drugs / G. B. Migliori [et al.] // Eurosurveillance (Weekly releases). – 2007. – Vol. 12, N 5. – E070517.1.

14. Bedaquiline and MDR-TB: a systematic and critical analysis of the evidence / E. Pontali [et al.] // Europ. Respiratory J. – 2016. – Vol. 47, N 2. – P. 394–402.

15. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update / D. Falzon [et al.] // Europ. Respiratory J. – 2011. – Vol. 38, N 3. – P. 516–528.

16. Caminero, J. A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence / J. A. Caminero, A. Scardigli // Europ. Respiratory J. – 2015. – Vol. 46, N 4. – P. 887–893.

17. Bedaquiline in the treatment of multi- and extensively drug-resistant tuberculosis / A. S. Pym [et al.] // Europ. Respiratory J. – 2016. – Vol. 47, N 2. – P. 564–574.

18. The diarylquinoline TMC207 for multidrug-resistant tuberculosis / A. H. Diacon [et al.] // New England J. of Medicine. – 2009. – Vol. 360, N 23. – P. 2397–2405.

19. Multidrug-resistant tuberculosis and culture conversion with bedaquiline / A. H. Diacon [et al.] // New England J. of Medicine. – 2014. –Vol. 371, N 8. – P. 723–732.

20. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort / L. Guglielmetti [et al.] // Clinical Infectious Diseases. – 2015. – Vol. 60, N 2. – P. 188–194.

21. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis / N. Ndjeka [et al.] // Intern. J. of Tuberculosis and Lung Disease. – 2015. – Vol. 19, N 8. – P. 979–985.

22. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use / S. Tiberi [et al.] // Europ. Respiratory J. – 2014. – Vol. 43, N 1. – P. 289–292.

23. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline / M. Tadolini [et al.] // Europ. Respiratory J. – 2016. – Vol. 48, N 3. – P. 935–938.

24. Wallis, R. S. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine / R. S. Wallis // Europ. Respiratory J. – 2016. – Vol. 48, N 5. – P. 1526–1527.

25. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine / M. Tadolini [et al.] // Europ. Respiratory J. – 2016. – Vol. 48, N 5. – P. 1527–1529.

26. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase / R. Meisel [et al.] // Leukemia. – 2011. – Vol. 25, N 4. – P. 648–654.

27. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis / S. Van Linthout [et al.] // Europ. Heart J. – 2010. – Vol. 32, N 17. – P. 2168–2178.

28. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis / Sh. H. J. Mei [et al.] // Amer. J. of Respiratory and Critical Care Medicine. – 2010. – Vol. 182, N 8. – P. 1047–1057.

29. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37 / A. Krasnodembskaya [et al.] // Stem Cells. – 2010. – Vol. 28, N 12. – P. 2229–2238.

30. Stem cell transplantation: the lung barrier / S. Schrepfer [et al.] // Transplantation Proc. – 2007. – Vol. 39, N 2. – P. 573–576.

31. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone / R. Sackstein [et al.] // Nature Medicine. – 2008. – Vol. 14, N 2. – P. 181–187.

32. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. / J. Gao [et al.] // Cells Tissues Organs. – 2001. – Vol. 169, N 1. – P. 12–20.

33. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. / I. M. Barbash [et al.] // Circulation. – 2003. – Vol. 108, N 7. – P. 863–868.

34. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 / R. H. Lee [et al.] // Cell Stem Cell. – 2009. – Vol. 5, N 1. – P. 54–63.

35. Therapeutic potential of mesenchymal stem cells for severe acute lung injury / M. A. Matthay [et al.] // Chest. – 2010. – Vol. 138, N 4. – P. 965–972.

36. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxininduced acute lung injury in mice / N. Gupta [et al.] // J. of Immunology. – 2007. – Vol. 179, N 3. – P. 1855–1863.

37. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats / F. Zhao [et al.] // Transplantation Proc. – 2008. – Vol. 40, N 5. – P. 1700–1705.

38. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects / L. A. Ortiz [et al.] // Proc. of the Nat. Acad. of Sciences. – 2003. – Vol. 100, N 14. – P. 8407–8411.